| Molecular formula | C50H63N13O7 |
|---|
| Molecular weight | 958.1 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 10011122 |
|---|
Key takeaways
- Alexamorelin has no FDA-approved label and no approved medical use.
- It is classified as an unapproved research compound.
- No clinical trials are currently registered for this compound.
- Its molecular formula is C50H63N13O7, with a molecular weight of approximately 958.1 g/mol.
What alexamorelin is
Alexamorelin is a synthetic peptide compound identified in chemical databases under PubChem CID 10011122. It has a molecular formula of C50H63N13O7 and a molecular weight of about 958.1 g/mol. There is no dedicated drug label on file for this compound, meaning no regulatory body has reviewed or approved it for any medical condition. Its structure, based on its canonical SMILES representation, includes multiple amino acid-like residues linked in a peptide chain.
Regulatory and research status
Alexamorelin is classified as an unapproved research compound. This means it has not undergone the formal review process required for pharmaceutical approval and carries no sanctioned indication, dosage, or safety profile. No clinical trials are currently registered in the tracked database for this compound, so there is no available human trial data to describe its testing history or developmental progress.
FAQ
No. Alexamorelin has no FDA-approved label and is classified as an unapproved research compound. No regulatory body has reviewed it for safety or effectiveness in any indication.
Based on available records, there are zero registered clinical trials for alexamorelin. This means there is no published human trial data to reference for this compound.
Alexamorelin has the molecular formula C50H63N13O7 and a molecular weight of approximately 958.1 g/mol. It is a peptide-based compound composed of multiple linked amino acid-like residues.
This designation means the substance has not been evaluated or authorized by a regulatory agency for any medical use. It is typically studied only in preliminary or laboratory settings rather than in approved clinical practice.
No side effect reporting data is currently available for alexamorelin. Without an approved label or trial history, there is no established safety profile to summarize.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 10011122 ClinicalTrials.gov registry search
Updated 2026-09-26